Calculi

ARUP offers a comprehensive menu to assess patients with kidney stone disease. Calculi (stone) testing specializes in two areas that provide valuable information to determine appropriate treatment and course of patient care:

1. Assessing and monitoring the risk of stone formation (urine studies)

2. Evaluating stone composition

Epidemiology

  • Approximately 11 percent of adults in the United States will develop kidney stones in their lifetime. These rates double in patients with a family history of stones.
  • Men are two to three times more likely than women to experience kidney stones.
  • The five-year recurrence rate is reported to be as high as 50 percent after the first episode.
  • Incidence of this disease is rising and estimated to cost $5.3 billion per year in healthcare dollars.

Test Information

Test Number Test Name
0020843 Kidney Stone Risk Panel, Urine
2008708 Calculi Risk Assessment, Urine
2008771 Supersaturation Profile, Urine
0099460 Calculi (Stone) Analysis
2005231 Calculi (Stone) Analysis with Photo
0081105 Cystinuria Panel
0081106 Cystine Quantitative, Urine
2009419 Amino Acids Quantitative by LC-MS/MS, Urine

 

ARUP has designed efficient urine panels that assess
stone-forming risk, monitor the course of therapy, and reduce testing expenses.

 

 

Benefits of Calculi Testing at ARUP

 

  • ARUP has designed efficient urine panels that assess stone-forming risk, monitor the course of therapy, and reduce testing expenses.
  • The Stone Crusher, developed by ARUP Bioengineering Department, analyzes stones to determine their composition, which helps guide therapy in patients with a history of stone formation.
  • This technology reduces processing errors and decreases turnaround time.
  • A full stone analysis with a photo is available through ARUP’s enhanced reporting system.

Additional Resources